Compare Crispr Therapeutics AG (CRSP) vs iShares Gold Trust (IAU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Gold Trust — how do they compare? Crispr Therapeutics AG trades at $50.85 (market cap $4.97B), while iShares Gold Trust trades at $76.4. The key difference: iShares Gold Trust is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | IAU | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $76.78 | $101.57 |
52-Week Low | $44.34 | $61.62 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
IAU, the iShares Gold Trust ETF, is trading at $75.25, down 2.6% with a bearish technical outlook. The ETF faces pressure from rising Treasury yields and Federal Reserve policy uncertainty, though recent weaker CPI data provided temporary support. Gold remains a key asset amid geopolitical tensions and central bank accumulation, with the fund offering low-cost exposure to physical gold.
The outlook for IAU is mixed, balancing strong long-term fundamentals against near-term headwinds. Gold's role as a hedge and central bank demand provide support, but Fed policy and dollar strength pose risks. The ETF's structure offers efficient gold access, but price volatility requires careful position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
